The results showed a reduction in airway hyperresponsiveness, a decrease in airway remodeling, and a decrease in inflammation. This is a groundbreaking development in the field of allergic asthma treatment, as it offers a potential first-line therapy that targets the underlying immune dysregulation. HpVac SA, based in Geneva, Switzerland, is a research-focused company dedicated to developing innovative preventive and therapeutic solutions for allergic and inflammatory diseases.

Their lead compound, HpVac-R13, is a recombinant molecule that harnesses the beneficial potential of gastric bacteria found in the human gut microbiome. With this breakthrough in their clinical studies, HpVac is poised to revolutionize the treatment of allergic diseases and provide much-needed relief for patients suffering from asthma and other allergic conditions